The 3D-Printed Bilayer's Bioactive-Biomaterials Scaffold for Full-Thickness Articular Cartilage Defects Treatment.

The full-thickness articular cartilage defect (FTAC) is an abnormally severe grade of articular cartilage (AC) injury. An osteochondral autograft transfer (OAT) is the recommended treatment, but the increasing morbidity rate from osteochondral plug harvesting is a limitation. Thus, the 3D-printed bilayer's bioactive-biomaterials scaffold is of major interest. Polylactic acid (PLA) and polycaprolactone (PCL) were blended with hydroxyapatite (HA) for the 3D-printed bone layer of the bilayer's bioactive-biomaterials scaffold (B-BBBS). Meanwhile, the blended PLA/PCL filament was 3D printed and combined with a chitosan (CS)/silk firoin (SF) using a lyophilization technique to fabricate the AC layer of the bilayer's bioactive-biomaterials scaffold (AC-BBBS). Material characterization and mechanical and biological tests were performed. The fabrication process consists of combining the 3D-printed structure (AC-BBBS and B-BBBS) and a lyophilized porous AC-BBBS. The morphology and printing abilities were investigated, and biological tests were performed. Finite element analysis (FEA) was performed to predict the maximum load that the bilayer's bioactive-biomaterials scaffold (BBBS) could carry. The presence of HA and CS/SF in the PLA/PCL structure increased cell proliferation. The FEA predicted the load carrying capacity to be up to 663.2 N. All tests indicated that it is possible for BBBS to be used in tissue engineering for AC and bone regeneration in FTAC treatment.

The Possibility of Interlocking Nail Fabrication from FFF 3D Printing PLA/PCL/HA Composites Coated by Local Silk Fibroin for Canine Bone Fracture Treatment.

The biomaterials polylactic acid (PLA), polycaprolactone (PCL), and hydroxyapatite (HA) were selected to fabricate composite filaments for 3D printing fused filament fabrication (FFF), which was used to fabricate a composite biomaterial for an interlocking nail for canine diaphyseal fractures instead of metal bioinert materials. Bioactive materials were used to increase biological activities and provide a high possibility for bone regeneration to eliminate the limitations of interlocking nails. HA was added to PLA and PCL granules in three ratios according to the percentage of HA: 0%, 5%, and 15% (PLA/PCL, PLA/PCL/5HA, and PLA/PCL/15HA, respectively), before the filaments were extruded. The test specimens were 3D-printed from the extruded composite filaments using an FFF printer. Then, a group of test specimens was coated by silk fibroin (SF) using the lyophilization technique to increase their biological properties. Mechanical, biological, and chemical characterizations were performed to investigate the properties of the composite biomaterials. The glass transition and melting temperatures of the copolymer were not influenced by the presence of HA in the PLA/PCL filaments. Meanwhile, the presence of HA in the PLA/PCL/15HA group resulted in the highest compressive strength (82.72 ± 1.76 MPa) and the lowest tensile strength (52.05 ± 2.44 MPa). HA provided higher bone cell proliferation, and higher values were observed in the SF coating group. Therefore, FFF 3D-printed filaments using composite materials with bioactive materials have a high potential for use in fabricating an interlocking nail for canine diaphyseal fractures.

Low-amplitude, left vagus nerve stimulation significantly attenuates ventricular dysfunction and infarct size through prevention of mitochondrial dysfunction during acute ischemia-reperfusion injury.

BACKGROUND: Right cervical vagus nerve stimulation (VNS) provides cardioprotective effects against acute ischemia-reperfusion injury in small animals. However, inconsistent findings have been reported. OBJECTIVE: To determine whether low-amplitude, left cervical VNS applied either intermittently or continuously imparts cardioprotection against acute ischemia-reperfusion injury. METHODS: Thirty-two isoflurane-anesthetized swine (25-30 kg) were randomized into 4 groups: control (sham operated, no VNS), continuous-VNS (C-VNS; 3.5 mA, 20 Hz), intermittent-VNS (I-VNS; continuously recurring cycles of 21-second ON, 30-second OFF), and I-VNS + atropine (1 mg/kg). Left cervical VNS was applied immediately after left anterior descending artery occlusion (60 minutes) and continued until the end of reperfusion (120 minutes). The ischemic and nonischemic myocardium was harvested for cardiac mitochondrial function assessment. RESULTS: VNS significantly reduced infarct size, improved ventricular function, decreased ventricular fibrillation episodes, and attenuated cardiac mitochondrial reactive oxygen species production, depolarization, and swelling, compared with the control group. However, I-VNS produced the most profound cardioprotective effects, particularly infarct size reduction and decreased ventricular fibrillation episodes, compared to both I-VNS + atropine and C-VNS. These beneficial effects of VNS were abolished by atropine. CONCLUSIONS: During ischemia-reperfusion injury, both C-VNS and I-VNS provide significant cardioprotective effects compared with I-VNS + atropine. These beneficial effects were abolished by muscarinic blockade, suggesting the importance of muscarinic receptor modulation during VNS. The protective effects of VNS could be due to its protection of mitochondrial function during ischemia-reperfusion.